Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding

Uterine Fibroids Clinical Trial

— DUAO  

Official title:

A Pivotal Study of Doppler Guided Uterine Artery Occlusion as Treatment for the Reduction of Fibroid Associated Bleeding

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00496080
• Other study ID #: 300-06-004
• Status: Terminated
• Phase: N/A
• First received: July 3, 2007
• Last updated: September 6, 2012
• Start date: June 2007
• Est. completion date: October 2010

Study information

• Verified date: September 2012
• Source: Ethicon, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationCanada: Health CanadaMexico: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate the safety and effectiveness of Doppler guided uterine artery occlusion (D-UAO) for the reduction of fibroid associated bleeding.

Description:

The GYNECARE GYNOCCLUDE D-UAO Instruments are single-use disposable instruments consisting of a GYNECARE GYNOCCLUDE Uterine Stabilizer, a GYNECARE GYNOCCLUDEM Introducer Sheath, a GYNECARE GYNOCCLUDE Doppler Clamp, and a GYNECARE GYNOCCLUDE Coupler.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 87
• Est. completion date: October 2010
• Est. primary completion date: September 2010
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 25 Years to 50 Years

Eligibility

Inclusion Criteria:

• 25 to 50 years of age;

• PBLAC score of 150 or greater;

• Completed child-bearing;

• Normal Pap smear within 12 months;

• Cervix suitable for tenaculum placement as determined by pelvic exam;

• At least one uterine fibroid of 3 cm diameter or greater with a prevailing pathology (e.g., as opposed to adenomyosis) of fibroids determined through ultrasound;

• Willing to maintain use or non-use of hormonal contraception from 3 months pre-study throughout the 12-month follow-up period;

• Willing to maintain use or non-use of anti-fibrinolytic agents from 3 months pre-study throughout the 12-month follow-up period;

• Able to tolerate the required prolonged supine position during treatment (approximately 6 hours);

• Willing and able to provide informed consent and to follow study-related requirements;

Exclusion Criteria:

• Pregnancy (as confirmed immediately prior to procedure)

• Fibroid diameter greater than 8.0 cm determined through transvaginal ultrasound; [or if 2 dimensions are measured, total dimension greater than 16 cm; or if the 3 dimensions (length, height, width) are measured, total dimension greater than 24 cm];

• Presence of a pedunculated fibroid determined by ultrasound; hysteroscopy, or saline infused sonography;

• Hydronephrosis as determined by radiologist interpretation on renal ultrasound pre-procedurally;

• Menopausal;

• Clinical history of any thromboembolic disease;

• Blood urine nitrogen (BUN) greater than 20 mg/dL and/or serum creatinine greater than 1.2 mg/dL unresolved with change in diet or hydration; · One or more lower uterine segment fibroids determined through pelvic exam;

• History of gynecologic malignancy, atypical endometrial hyperplasia, or pelvic inflammatory disease;

• Abnormal endometrial biopsy within the last 6 months prior to procedure;

• Pelvic mass outside the uterus suggesting other disease processes;

• Any current acute or chronic systemic infection or localized pelvic infection, including an unresolved urinary tract infection;

• Using GnRH agonist or mifepristone within 6-months prior to the start of the study;

• An intrauterine device (IUD) in place;

• Using anticoagulation therapy (except OTC treatments (e.g. aspirin)), or have an underlying bleeding disorder;

• Unsuitable for MRI examination, if within study subgroup to undergo MRI evaluation (e.g. severe claustrophobia, non-MRI-compatible implanted metalloid devices);

• Prior endometrial ablation, uterine artery embolization, or uterine artery ligation;

• Poor procedural candidate due to medical conditions as determined by the investigator (e.g. anesthesia class, renal insufficiency, heart disease);

• Grade 1 for 3D Color Doppler or no flow observed for cystoscopy on ureter flow assessment if applicable.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Leiomyoma
• Menorrhagia
• Uterine Fibroids

Intervention

Device:
• Doppler-Guided Uterine Artery Occlusion Device (DUAO)
Investigational transvaginal clamp inserted one time for 6 hours.

Locations

Country	Name	City	State
Canada	St. Joseph's Health Care	London	Ontario
Mexico	Hospital Universitario	Monterrey	Nuevo Leon
United States	Matlock Ob/Gyn	Arlington	Texas
United States	North Carolina Children's & Adults' Clinical Research Foundation	Chapel Hill	North Carolina
United States	St. Luke's Hospital	Chesterfield	Missouri
United States	Complete Healthcare for Women	Columbus	Ohio
United States	Minnesota Gynecology and Surgery	Edina	Minnesota
United States	Holy Cross Medical Group	Fort Lauderdale	Florida
United States	Hahnemann University Hospital - Drexel University School of Med.	Philadelphia	Pennsylvania
United States	Women's Health Research	Phoenix	Arizona
United States	University Women's Care - Wayne State University	Southfield	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Ethicon, Inc.

Countries where clinical trial is conducted

United States,  Canada,  Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	No Surgical Re-intervention	Number of participants without any subsequent surgical procedure intended to manage fibroid symptoms performed. Potential procedures included surgical hysterectomy or dilatation and curettage (D&C) for treatment of menorrhagia; uterine artery embolization (UAE) or laparoscopic uterine artery occlusion; endometrial resection or ablation; myomectomy or myolysis.	Study completion	No
Primary	Improvement in Pictorial Blood Loss Assessment Chart (PBLAC) Score	Number of participants with a 50% or greater reduction in PBLAC score from baseline at 12 mo and a PBLAC score of less than 250. PBLAC is a simple validated semiquantitative method of measuring total menstrual blood loss using a pictorial representation of blood loss, where higher scores indicate more blood loss. This hybrid endpoint combined the reduction in PBLAC score with the total PBLAC score.	From baseline to 12 months	No
Secondary	Mean Improvement in Health Related Quality of Life (HRQOL) Scores	Participants categorized as "better" in the total UFS-QOL questionnaire, indicating an overall improvement in health-related quality of life. On this scale, higher scores are indicative of better quality of life, with a maximum(best)score of 100 and a minimum (worst)score of 0. "Better" was defined as a change of +12 or more from baseline at 12 mo.	From baseline to 12 months	No
Secondary	Maintenance of Menses	Number of participants with continuation of menstrual cycles without interruption for three consecutive months	12 months	No
Secondary	Procedural Satisfaction	Number of participants with responses of either "satisfied" or "very satisfied" on a qualitative survey that ranged from "very dissatisfied" (worst) to "very satisfied" (best)	12 months	No
Secondary	Decrease in Fibroid Bulk	Number of participants with a minimum 15% decrease in fibroid bulk based on independent magnetic resonance imaging (MRI) review from baseline at 12 mo.; Note: As per protocol, MRIs were planned only for subjects 1 - 40, 81 - 120, and 161-200.	From baseline to 12-months	No
Secondary	Mean Improvement in Uterine Fibroid Symptom Quality of Life (UFS-QOL) Symptom Severity Scores	Number of participants categorized as "better" in the UFS-QOL sympton severity questionnaire, indicating an overall improvement in fibroid related symptoms. On this scale, higher scores are indicative of increasing symptom distress, with a maximum(worst)score of 100 and a minimum (best)score of 0. "Better" was defined as a change of -11 or less from baseline at 12 mo.	From baseline to 12 months	No